MP59-06 POST-TREATMENT SURVEILLANCE PRACTICE PATTERNS FOR STAGE T1 RENAL CELL CARCINOMA

You have accessJournal of UrologyKidney Cancer: Localized: Surgical Therapy VI1 Apr 2018MP59-06 POST-TREATMENT SURVEILLANCE PRACTICE PATTERNS FOR STAGE T1 RENAL CELL CARCINOMA Neal A. Patel, Christopher Gaffney, Adrien Bernstein, Tianyi Sun, Art Sedrakyan, and Jim C. Hu Neal A. PatelNeal A. Patel More articles by this author , Christopher GaffneyChristopher Gaffney More articles by this author , Adrien BernsteinAdrien Bernstein More articles by this author , Tianyi SunTianyi Sun More articles by this author , Art SedrakyanArt Sedrakyan More articles by this author , and Jim C. HuJim C. Hu More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.1858AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Time to recurrence after nephron sparing treatment of renal cell carcinoma varies based on stage. However, national committees often recommend the same post treatment surveillance strategies for all T1 renal cell carcinomas. In this population based study, we sought to evaluate clinical practice patterns for post treatment imaging for stage T1 renal cell carcinomas. METHODS We identified all patients with T1 renal cell carcinoma treated with partial nephrectomy or ablation between 2004-2014 using Surveillance, Epidemiology and End Results-Medicare(SEER). Annual abdominal imaging for patients for 3 years after treatment was queried. If a patient did not have follow-up with a medical oncologist, urologist or interventional radiologist or died within a given year, they were excluded from subsequent analysis. The association between clinical characteristics and complete abdominal imaging per national guidelines was assessed using logistic regression. RESULTS A total of 2204 patients (1821 T1a and 383 T1b) underwent partial nephrectomy or renal ablation. 94.8% of T1a and 93.6% of T1b patients had abdominal imaging at least once in the post-treatment setting (p=0.33). 44.6% of T1a and 46.4% of T1b patients had abdominal imaging 3 years after their initial post-operative imaging (p=0.64). Unadjusted logistic regression showed that patients older than 80 (OR 0.62, 95% CI 0.42-0.92, p=0.02) were less likely to have continued surveillance for treated T1a masses. Postoperative follow-up with a medical oncologist was associated with longer surveillance for treated T1b masses (OR 3.59, 95% CI 1.23-10.50, p=0.02). CONCLUSIONS A large portion of patients treated for stage T1 renal cell carcinoma do not receive complete abdominal surveillance as outline by national committee guidelines. Given that the median time to recurrence for T1 masses is approximately two years, several local recurrences would be missed with current surveillance patterns. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e783 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Neal A. Patel More articles by this author Christopher Gaffney More articles by this author Adrien Bernstein More articles by this author Tianyi Sun More articles by this author Art Sedrakyan More articles by this author Jim C. Hu More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...